AzTrials
AzTrials

Dietary SupplementsNCT01011517

Muscadine Grape Seed Supplementation and Vascular Function

A study testing Muscadine grape seed supplement in people with Dietary Supplements, run by Wake Forest University Health Sciences at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The investigators sought to evaluate the effect of muscadine grape seed supplementation on brachial diameter and flow-mediated vasodilator responses in subjects with, or at risk for cardiovascular disease. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Dietary Supplements
What is being tested?
Muscadine grape seed supplement
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
50 participants
Where
1 siteUnited States
Study dates
Jun 2007to Sep 2008
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • adult male and non-pregnant female outpatients, with
  • hypertension (blood pressure ≥ 140/90 or current treatment for hypertension), or
  • dyslipidemia (total cholesterol > 220 mg/dL + LDL cholesterol > 130 mg/dL, or current use of lipid-lowering medications), or
  • controlled type 2 diabetes mellitus (glycated hemoglobin < 8.0 % with or without medication).

Who cannot join

  • history of congestive heart failure (any classification)
  • unstable angina or acute coronary syndrome within the last 30 days,
  • uncontrolled hypertension (blood pressure ≥ 170/100 mm/Hg),
  • type 1 diabetes mellitus,
  • uncontrolled type 2 diabetes mellitus (HbA1C ≥ 8.0%),
  • history of gastrointestinal disease or surgery affecting absorption,
Show all 13Show fewer
  • peripheral arterial disease,
  • diagnosis of active cancer (excluding squamous cell or basal cell skin cancer),
  • current use of long-acting nitrate compounds such as isosorbide dinitrate or nitroglycerin,
  • recent change in any medications (last 30 days),
  • active plan to change diet or exercise patterns,
  • history of hypersensitivity to any compound in the intervention or placebo,
  • history of intolerance to nitrates

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Wake Forest University School of Medicine

    Winston-Salem, North Carolina, 27157

Other trials in United States

About this study

Official title: Effect of Muscadine Grape Seed Supplementation on Vascular Function in Subjects With or at Risk for Cardiovascular Disease: A Randomized Crossover Trial

The investigators sought to evaluate the effect of muscadine grape seed supplementation on brachial diameter and flow-mediated vasodilator responses in subjects with, or at risk for cardiovascular disease.

Methods: In a randomized, double-blind, placebo-controlled crossover trial, 50 adults (25 men, 25 women) with one or more cardiac risk factors were randomized to muscadine grape seed (MGS) supplement 1300mg daily vs.. placebo for 4 weeks each, with a 4-week washout between study periods. Resting diameter and endothelial function measured using brachial flow-mediated dilation (FMD) were determined at the beginning and end of each study period.

Read the detailed description

Study Participants Participants were adult male and non-pregnant female outpatients ages 18-65 with one or more of the following cardiovascular risk factors: hypertension (blood pressure ≥ 140/90 or current treatment for hypertension); dyslipidemia (total cholesterol > 220 mg/dL + LDL cholesterol > 130 mg/dL, or current use of lipid-lowering medications); or controlled type 2 diabetes mellitus (glycated hemoglobin < 8.0 % with or without medication). Subjects with a history of coronary artery disease (any history of myocardial infarction or coronary revascularization) were also eligible for participation. Subjects were excluded if they had a history of congestive heart failure (any classification), unstable angina or acute coronary syndrome within the last 30 days, uncontrolled hypertension (blood pressure ≥ 170/100 mm/Hg), type 1 diabetes mellitus, uncontrolled type 2 diabetes mellitus (HbA1C ≥ 8.0%), history of gastrointestinal disease or surgery affecting absorption, peripheral arterial disease, diagnosis of active cancer (excluding squamous cell or basal cell skin cancer), current use of long-acting nitrate compounds such as isosorbide dinitrate or nitroglycerin, recent change in any medications (last 30 days), active plan to change diet or exercise patterns, history of hypersensitivity to any compound in the intervention or placebo, or history of intolerance to nitrates.

Study Design The study was a double-blind, randomized crossover design to evaluate the effects of muscadine grape seed supplementation (Nature's Pearl 650 mg, two capsules daily.) The phytochemical profile of the supplement is presented in Table 1. The trial consisted of a screening visit followed by baseline and closeout visits for two study treatment periods (4 weeks each), separated by a 4-week washout period (total of 5 visits over 14 weeks).Endothelial function was assessed at the beginning and end of each study period using brachial artery flow-mediated dilation (brachial FMD - described below). A fasting blood sample was obtained at the open and close of each study period for measurement of lipids, inflammatory markers, and markers of antioxidant capacity and oxidative stress. Participants were asked to abstain from red wine, antioxidant vitamin supplements (including vitamin E, vitamin C, and beta-carotene supplements, more than 1 cup of black or green tea daily, and other grape seed supplements. Multivitamin supplements were permitted as long as they were taken for the study duration.

Endothelial Function Study Protocol Details for the brachial FMD protocol, automated analysis and reproducibility have been published previously {Herrington 2001}. Briefly, subjects rested in a quiet, temperature-controlled room for 15 minutes. A standard (pediatric) cuff was placed on the right forearm 2 inches (5 cm) below the antecubital fossa. Once the transducer position was established over the left brachial artery, continuous scanning of the brachial artery was obtained for 2 minutes before the cuff occlusion, 4 minutes of cuff occlusion, and 2 minutes immediately after cuff release. Data were analyzed with an automated analysis system that determines changes in brachial artery diameter for 2 minutes after cuff release.

Statistical Analysis The effects of supplementation with muscadine grape seeds and placebo were compared using paired t-tests and mixed linear models to take into account treatment order and period effects. The mixed linear models were also used to formally test for a residual effect of treatment in those subjects receiving active treatment in the first treatment period. Stratified analyses were performed to look for evidence of differential effects by age, gender, prevalent heart disease or heart disease risk factors. Nominal 2-tailed p-values are presented for the primary outcome (percent change in brachial diameter) and for all secondary outcomes. All analyses were performed using SAS v. 9.1 (Cary, NC).

Being tested
Muscadine grape seed supplement
Keywords
muscadine grapes, endothelial function

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Muscadine grape seed supplementDietary supplement

    Also called Nature's Pearl 650 mg, two capsules daily

    Nature's Pearl 650 mg, two capsules daily

Study groups in NCT01011517
Study groupRoleWhat they receive
grape seed supplementExperimentalNature's Pearl 650 mg, two capsules daily
Receives: Dietary Supplement: Muscadine grape seed supplement
placeboPlacebo comparatorplacebo
Receives: Dietary Supplement: Muscadine grape seed supplement

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Brachial Artery Flow mediated dilation

    Measured: 1 month

Secondary outcomes (1)
  1. Plasma markers of inflammation and anitoxidant capacity

    Measured: 1 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Nov 2009 (estimated)
  2. Study startJun 2007
  3. Primary completionDec 2007
  4. Study completionSep 2008

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Crossover
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
50 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01011517
Sponsor's protocol ID
IRB00002611
Status last verified
Aug 2018
First submitted
10 Nov 2009
Last updated
9 Aug 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Muscadine grape seed supplement in people with Dietary Supplements, run by Wake Forest University Health Sciences at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Brachial Artery Flow mediated dilation (time frame: 1 month). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Aug 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in